Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2001

View Archived Issues

Canadian neuroprotection research collaboration announced

NDA submission for King's injectable estrogen replacement therapy

Positive results obtained in phase II trial of phenserine in Alzheimer's patients

Axcan to acquire Enteris

Amersham Health to develop and market Bexxar in Europe

Ribi-529 adjuvant added to Corixa/Wyeth Lederle Vaccines license agreement

Lilly receives approvable letter from FDA for Xigris

Preclinical and clinical data for Tularik's lead anti-HCMV agent discussed at IDSA

Human pharmacokinetic/drug interaction and resistance data reported at IDSA for ABT-773

BMS-284756 preclinical and clinical results a highlight of the IDSA meeting

Ariad continues to strengthen product pipeline

Celebrex indications expanded with recent FDA approval

Medivir summarizes clinical and preclinical project progress

Interim findings from single-dose human trial support further clinical evaluation of MDX-010

Development of antipsychotic 5-HT2A inverse agonist initiated by Acadia

Dual topoisomerase I and II inhibitor shows promise for colon cancer

MTD not reached in ongoing phase I trials of PKI-166, an EGF receptor tyrosine kinase inhibitor

Company Profile: Biovitrum

New tablet formulations of linezolid claimed by Pharmacia

Tanox designs anticomplement monoclonal antibodies for autoimmune and inflammatory diseases

New indoles acting as DP receptor antagonists in the Ono pipeline

Gastric prokinetic agents with a hydroxyethoxybenzamide structure synthesized at Kissei

Kuraray patents new compounds for use in breast cancer

Baxter acquires Asta Medica Oncology

European mutual recognition procedure completed for Estradot

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...